Bath Savings Trust Co Sells 400 Shares of Bristol-Myers Squibb (NYSE:BMY)

Bath Savings Trust Co cut its position in shares of Bristol-Myers Squibb (NYSE:BMY) by 4.2% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,195 shares of the biopharmaceutical company’s stock after selling 400 shares during the quarter. Bath Savings Trust Co’s holdings in Bristol-Myers Squibb were worth $520,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Lantz Financial LLC grew its holdings in shares of Bristol-Myers Squibb by 17.4% during the 2nd quarter. Lantz Financial LLC now owns 11,799 shares of the biopharmaceutical company’s stock valued at $490,000 after purchasing an additional 1,747 shares during the last quarter. Chris Bulman Inc bought a new position in shares of Bristol-Myers Squibb during the second quarter valued at about $48,000. Caprock Group LLC increased its holdings in shares of Bristol-Myers Squibb by 56.0% in the second quarter. Caprock Group LLC now owns 44,767 shares of the biopharmaceutical company’s stock worth $1,859,000 after buying an additional 16,069 shares during the period. Quest Partners LLC boosted its holdings in Bristol-Myers Squibb by 29,957.4% during the 2nd quarter. Quest Partners LLC now owns 40,878 shares of the biopharmaceutical company’s stock valued at $1,698,000 after acquiring an additional 40,742 shares during the period. Finally, First Foundation Advisors grew its position in Bristol-Myers Squibb by 73.0% during the 2nd quarter. First Foundation Advisors now owns 5,656 shares of the biopharmaceutical company’s stock worth $235,000 after acquiring an additional 2,386 shares during the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 1,830 shares of the stock in a transaction that occurred on Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the transaction, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 3.04 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Phil M. Holzer sold 700 shares of the stock in a transaction on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the transaction, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. The trade was a 5.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.09% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on the company. Daiwa America raised Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, November 13th. Citigroup boosted their price target on Bristol-Myers Squibb from $55.00 to $60.00 and gave the company a “neutral” rating in a report on Tuesday, November 12th. Wolfe Research began coverage on Bristol-Myers Squibb in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Barclays boosted their target price on Bristol-Myers Squibb from $42.00 to $43.00 and gave the company an “underweight” rating in a research note on Monday, October 7th. Finally, BMO Capital Markets raised their price target on Bristol-Myers Squibb from $57.00 to $61.00 and gave the stock a “market perform” rating in a research note on Tuesday, November 12th. Two investment analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $55.64.

Bristol-Myers Squibb Stock Up 1.3 %

Shares of NYSE BMY traded up $0.74 during trading on Tuesday, reaching $57.42. The company had a trading volume of 4,842,917 shares, compared to its average volume of 8,201,315. Bristol-Myers Squibb has a 12-month low of $39.35 and a 12-month high of $61.08. The company has a quick ratio of 1.09, a current ratio of 1.24 and a debt-to-equity ratio of 2.83. The business’s 50-day moving average is $57.22 and its 200 day moving average is $51.15. The stock has a market cap of $116.46 billion, a PE ratio of -15.99, a P/E/G ratio of 15.20 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY) last released its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.49 by $0.31. The business had revenue of $11.89 billion during the quarter, compared to analyst estimates of $11.26 billion. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. Bristol-Myers Squibb’s revenue was up 8.4% compared to the same quarter last year. During the same period last year, the business earned $2.00 EPS. As a group, equities analysts forecast that Bristol-Myers Squibb will post 0.93 earnings per share for the current fiscal year.

Bristol-Myers Squibb Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, February 3rd. Investors of record on Friday, January 3rd will be issued a $0.62 dividend. This represents a $2.48 annualized dividend and a yield of 4.32%. This is an increase from Bristol-Myers Squibb’s previous quarterly dividend of $0.60. The ex-dividend date of this dividend is Friday, January 3rd. Bristol-Myers Squibb’s dividend payout ratio (DPR) is presently -69.08%.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.